Scholarlink

<p>This Letter to the Editor raises concerns about the increased incidence of heart failure observed in the mepolizumab group in the MATINEE trial. Given the high cardiovascular burden in COPD patients, we highlight possible biological mechanisms and population-level implications, and urge further evaluation of heart failure risk before expanding the clinical use of IL-5–targeting biologics in eosinophilic COPD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Heart failure signal with mepolizumab in eosinophilic COPD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月20日

查看全文
  • Zhican Liu,
  • Lingling Zhang,
  • Mingyan Jiang

摘要

This Letter to the Editor raises concerns about the increased incidence of heart failure observed in the mepolizumab group in the MATINEE trial. Given the high cardiovascular burden in COPD patients, we highlight possible biological mechanisms and population-level implications, and urge further evaluation of heart failure risk before expanding the clinical use of IL-5–targeting biologics in eosinophilic COPD.